KALA BIO, Inc.(KALA)

Biotechnology · Arlington, MA

$0.38+0.01 (+3.81%)

Delayed quote: Oct 6, 2026, 11:24 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:27:30.424Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:27:30.424Z.

Quote observation: 2026-10-06T15:24:26.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 7,277,567
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 229,000
TTM free cash flow · period ending 2026-06-30: -19,895,000

FMP input reference: 2fde06f259e28fcaf0a0d51df993d991938700e907f86078bced96cac1655d96

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KALA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

KALA Competitors' EV/FCF Ratio

KALA

KALA BIO, Inc.

Current

Market Cap

$7.28M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INM

InMed Pharmaceuticals Inc.

vs KALA

Market Cap

$7.31M

EV/FCF Ratio

N/A

TTM Avg

41004.37x

3Y Avg

41004.37x

5Y Avg

41004.37x

CURX

Curanex Pharmaceuticals Inc Common Stock

vs KALA

Market Cap

$7.24M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LGVN

Longeveron Inc.

vs KALA

Market Cap

$7.43M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CODX

Co-Diagnostics, Inc.

vs KALA

Market Cap

$7.13M

EV/FCF Ratio

N/A

TTM Avg

1.99x

3Y Avg

10.75x

5Y Avg

10.75x

NRSN

NeuroSense Therapeutics Ltd.

vs KALA

Market Cap

$7.02M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGRX

Mangoceuticals, Inc.

vs KALA

Market Cap

$6.98M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNSP

CNS Pharmaceuticals, Inc.

vs KALA

Market Cap

$7.86M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACON

Aclarion, Inc.

vs KALA

Market Cap

$6.66M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HSCS

HeartSciences Inc.

vs KALA

Market Cap

$7.90M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
KALA BIO, Inc. (KALA)	$7.28M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.31M	N/A	41004.37x	41004.37x	41004.37x
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.24M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.43M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$7.13M	N/A	1.99x	10.75x	10.75x
NeuroSense Therapeutics Ltd. (NRSN)vs ›	$7.02M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$6.98M	N/A	N/A	N/A	N/A
CNS Pharmaceuticals, Inc. (CNSP)vs ›	$7.86M	N/A	N/A	N/A	N/A
Aclarion, Inc. (ACON)vs ›	$6.66M	N/A	N/A	N/A	N/A
HeartSciences Inc. (HSCS)vs ›	$7.90M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

KALA EV/FCF Ratio Metrics

KALA Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics